Paul Tudor Jones Akero Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

$44 Billion
Q2 2025

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 4,674 shares of AKRO stock, worth $253,517. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,674

Previous 45,001 89.61%

Holding current value

$253,517

Previous $1.82 Million 86.33%

% of portfolio

0.0%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$34.04 - $56.28 $1.37 Million - $2.27 Million	-40,327 Reduced 89.61%	4,674 $249,000
Q1 2025 May 15, 2025	BUY	$21.87 - $57.56 $223,227 - $587,514	10,207 Added 29.34%	45,001 $1.82 Million
Q4 2024 Feb 14, 2025	BUY	$26.75 - $35.28 $4,280 - $5,644	160 Added 0.46%	34,794 $967,000
Q3 2024 Nov 14, 2024	BUY	$21.45 - $29.34 $6,756 - $9,242	315 Added 0.92%	34,634 $993,000
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $34,349 - $46,187	-1,876 Reduced 5.18%	34,319 $805,000
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $642,823 - $1.13 Million	36,195 New	36,195 $914,000
Q3 2023 Nov 15, 2023	BUY	$41.19 - $52.25 $1.31 Million - $1.67 Million	31,881 New	31,881 $1.61 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $517,568 - $697,682	13,887 Added 60.38%	36,885 $1.41 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $362,890 - $594,689	10,852 Added 89.35%	22,998 $1.26 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $123,281 - $413,571	12,146 New	12,146 $414,000

Others Institutions Holding AKRO

# of Institutions

299

Shares Held

92.3M

Call Options Held

1.72M

Put Options Held

901K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.52B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account